CRP and spondylitis: Generics of tofacitinib are widely accessible in India, providing substantial cost reductions and reducing monthly therapy expenses to 1/10th of the original molecule's cost. Evidence on its efficacy is scarce, but a recent, small-scale, single-center, retrospective study from India, published in 2023, shows that tofacitinib generics significantly reduced the Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) score in patients and demonstrated a good safety profile [15].